

Michela Faggioni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5107422/publications.pdf>

Version: 2024-02-01

55
papers

1,515
citations

361388

20
h-index

315719

38
g-index

73
all docs

73
docs citations

73
times ranked

2882
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of Cardiac Ca ²⁺ Release Channels (RyR2) Determines Efficacy of Class I Antiarrhythmic Drugs in Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011, 4, 128-135.	4.8	137
2	Divergent Regulation of Ryanodine Receptor 2 Calcium Release Channels by Arrhythmogenic Human Calmodulin Missense Mutants. <i>Circulation Research</i> , 2014, 114, 1114-1124.	4.5	126
3	Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3055-3066.	2.8	117
4	Cerebral Embolic Protection During TAVR. <i>Journal of the American College of Cardiology</i> , 2017, 69, 465-466.	2.8	88
5	Acute and 30-Day Outcomes in Women After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1589-1600.	2.9	85
6	Comparison of Percutaneous Mitral Valve Repair Versus Conservative Treatment in Severe Functional Mitral Regurgitation. <i>American Journal of Cardiology</i> , 2016, 117, 271-277.	1.6	72
7	Ferritin as a reporter gene for in vivo tracking of stem cells by 1.5-T cardiac MRI in a rat model of myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H2238-H2250.	3.2	71
8	Calsequestrin 2 and arrhythmias. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H1250-H1260.	3.2	63
9	Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2124-2133.	2.9	58
10	Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 629-637.	1.7	56
11	Suppression of Spontaneous Ca Elevations Prevents Atrial Fibrillation in Calsequestrin 2-Null Hearts. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 313-320.	4.8	52
12	Accelerated Sinus Rhythm Prevents Catecholaminergic Polymorphic Ventricular Tachycardia in Mice and in Patients. <i>Circulation Research</i> , 2013, 112, 689-697.	4.5	50
13	Focal Energy Deprivation Underlies Arrhythmia Susceptibility in Mice With Calcium-Sensitized Myofilaments. <i>Circulation Research</i> , 2013, 112, 1334-1344.	4.5	42
14	Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2017-2025.	2.9	41
15	Calsequestrin Mutations and Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Pediatric Cardiology</i> , 2012, 33, 959-967.	1.3	40
16	Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1601-1610.	2.9	31
17	Preventing Contrast-induced Renal Failure: A Guide. <i>Interventional Cardiology Review</i> , 2016, 11, 98.	1.6	28
18	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 68-76.	2.9	28

#	ARTICLE	IF	CITATIONS
19	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	6.1	25
20	Culprit-lesion only versus complete multivessel percutaneous intervention in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2016, 220, 251-259.	1.7	21
21	Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: Risk factor and potential therapeutic target?. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 273-278.	4.9	20
22	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1638-1646.	1.6	19
23	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 645-654.	2.9	17
24	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007133.	3.9	17
25	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E112-E119.	1.7	16
26	The Purkinje-myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT. <i>JCI Insight</i> , 2022, 7, .	5.0	16
27	State of Fluoroless Procedures in Cardiac Electrophysiology Practice. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2020, 11, 4018-4029.	0.5	14
28	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E217-E225.	1.7	13
29	Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 119, 1166-1172.	1.6	12
30	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 983-992.	2.9	12
31	Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2019, 275, 31-35.	1.7	12
32	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017, 243, 132-139.	1.7	11
33	Dual-Imaging Stress Echocardiography for Prognostic Assessment of High-Risk Asymptomatic Patients with Diabetes Mellitus. <i>Journal of the American Society of Echocardiography</i> , 2017, 30, 149-158.	2.8	11
34	Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload. <i>Frontiers in Physiology</i> , 2019, 10, 992.	2.8	11
35	Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 298-308.	1.7	11
36	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2020, 125, 441-448.	1.6	9

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12457.	2.5	8
38	Epicardial Ablation Complications. <i>Cardiac Electrophysiology Clinics</i> , 2020, 12, 409-418.	1.7	8
39	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. <i>American Heart Journal</i> , 2019, 207, 10-18.	2.7	7
40	Arrhythmia Protection in Hypokalemia. <i>Circulation</i> , 2015, 132, 1371-1373.	1.6	6
41	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1704-1711.	3.4	2
42	Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 53-60.	1.7	2
43	Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study). <i>American Journal of Cardiology</i> , 2020, 125, 685-693.	1.6	1
44	Regional Connexin43 De-Phosphorylation and AMP-Kinase Activation after Rapid Pacing in Myofilament Ca Sensitized Hearts. <i>Biophysical Journal</i> , 2012, 102, 108a.	0.5	0
45	CABG Beats Vintage PCI. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2508-2510.	2.9	0
46	TCT-219 Influence Of Anemia On Physician-Recommended DAPT Discontinuation After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016, 68, B89.	2.8	0
47	Target lesion failure with BRS? good old DES to the rescue. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 837-838.	1.7	0
48	ANGIOGRAPHIC PHENOTYPE AND CLINICAL OUTCOMES OF PATIENTS WITH MALIGNANCY UNDERGOING PCI. <i>Journal of the American College of Cardiology</i> , 2017, 69, 117.	2.8	0
49	CLINICAL OUTCOMES ASSOCIATED WITH IMPELLA VERSUS IABP USE IN STABLE PATIENTS UNDERGOING HIGH RISK PERCUTANEOUS CORONARY INTERVENTION. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1117.	2.8	0
50	PREDICTORS OF HIGH INTENSITY STATIN USE AFTER PERCUTANEOUS CORONARY INTERVENTIONS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1272.	2.8	0
51	UNDERUTILIZATION OF HIGH INTENSITY STATINS IN A CONTEMPORARY HIGH RISK PCI POPULATION. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1352.	2.8	0
52	PREDICTION OF ACUTE KIDNEY INJURY IN PATIENTS UNDERGOING CORONARY INTERVENTION USING CALCULATION OF SERUM OSMOLALITY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1373.	2.8	0
53	Coronary Artery Stenting. <i>Contemporary Cardiology</i> , 2019, , 273-290.	0.1	0
54	Guest Editorial A Brave New World for Non-vitamin K Antagonist Oral Anticoagulants: Have We seen the Last of Warfarin?. <i>US Cardiology Review</i> , 2017, 11, 37.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Long-term Outcome of Pulmonary Vein Isolation Versus Amiodarone Therapy in Patients with Coexistent Persistent AF and Congestive Heart Failure. <i>Cardiac Failure Review</i> , 2020, 6, e04.	3.0	0